Board of the Pension Protection Fund Acquires Shares of 4,900 DaVita Inc. (NYSE:DVA)

Board of the Pension Protection Fund purchased a new stake in DaVita Inc. (NYSE:DVA - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 4,900 shares of the company's stock, valued at approximately $733,000.

Other hedge funds also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock valued at $99,846,000 after buying an additional 92,014 shares in the last quarter. KBC Group NV grew its position in DaVita by 27.3% in the third quarter. KBC Group NV now owns 313,519 shares of the company's stock valued at $51,395,000 after acquiring an additional 67,250 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of DaVita by 23.9% during the third quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company's stock valued at $47,874,000 after purchasing an additional 56,389 shares during the period. Nordea Investment Management AB boosted its position in DaVita by 4.9% in the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock valued at $39,712,000 after buying an additional 12,339 shares during the last quarter. Finally, abrdn plc grew its stake in shares of DaVita by 1.2% during the third quarter. abrdn plc now owns 189,065 shares of the company's stock valued at $30,719,000 after acquiring an additional 2,180 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Barclays boosted their price target on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. Truist Financial lifted their price objective on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $161.80.

DaVita Stock Performance

DaVita stock traded up $0.32 during midday trading on Wednesday, reaching $162.32. 478,619 shares of the stock traded hands, compared to its average volume of 590,191. DaVita Inc. has a fifty-two week low of $103.40 and a fifty-two week high of $169.51. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The firm has a market cap of $13.31 billion, a price-to-earnings ratio of 17.51, a PEG ratio of 0.86 and a beta of 0.92. The firm has a fifty day moving average price of $156.19 and a two-hundred day moving average price of $152.37.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the previous year, the firm earned $2.85 EPS. The firm's revenue was up 4.6% on a year-over-year basis. On average, equities research analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.